Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Ascorbic acid injection

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Ascorbic acid injection (opens in a new tab)Original source URL: https://globalrph.com/dilution/ascorbic-acid-injection/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/ascorbic-acid-injection/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:46:03.041749+00:00
Source location
div.post-content
Packaged content SHA-256
4ad218a6b0356c546ee0880c0b49e5a3ec76b5e2a201a4b0ed975da1f4a76124
Original response SHA-256
ccd360b1cb4f74abf65ef7ac5ca249df23f0345eb0137af318ac3339e6b0bc5a
Source body SHA-256
b43a5d4f8dc534cfc72a9f8f66b57fba7dbf30bed78ba5a40db7b492792d4c43

ASCOR (ascorbic acid injection), for intravenous use

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information (pdf)]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

D5W, NS

No degradation at 24 hours when D5W used. Review stability data below.

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

Sample dilutions:
[1500mg ] [50 mL ] [30 minutes]
[3000 mg ] [100 mL ] [30-60 minutes]
Rates of infusion may depend on whether or not the patient has a central line and the prescribed dose. Use our specialized calculator:
https://globalrph.com/medcalcs/ascorbic-acid-infusion-data/

Recent studies:

Reference Return to article top

ClinicalTrials.gov

  • Link
  • Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS). However, it is not known if early administration of HDIVC could prevent progression to ARDS.
  • We hypothesize that HDIVC is safe and tolerable in Coronavirus disease 2019 (COVID-19) subjects given early or late in the disease course and may reduce the risk of respiratory failure requiring mechanical ventilation and development of ARDS along with reductions in supplemental oxygen demand and inflammatory markers

Drug: ascorbic acid
50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)

Reference Return to article top

ClinicalTrials.gov

  • Link

  • Despite an organized treatment approach outlined in expert-consensus guidelines for sepsis with fluid resuscitation to treat hypovolemia, antibiotics to target the infectious insult, and vasopressors for hypotension, mortality rates for sepsis remain high and the incidence continues to rise, making sepsis the most expensive inpatient disease.

    1. Recent research has described the therapeutic benefits associated with ascorbic acid treatment for sepsis.
    2. Researchers objectives are to perform a randomized-controlled clinical trial investigating the ability of ascorbic acid(vitamin C) administration to decrease organ dysfunction in severe sepsis. The widespread occurrence of microvascular dysfunction in sepsis leading to tissue hypoxia, mitochondrial dysfunction, and ATP depletion, gives rise to organ failure.
    3. Patients with organ failure and sepsis (severe sepsis) are at a higher risk of death than patients with organ failure alone. Critically ill patients may have an increased requirement for ascorbic acid in sepsis and these patients frequently have levels below normal. Ascorbic acid administration, has been shown to correlate inversely with organ failure (human literature) and directly with survival (animal studies).
  • Intravenous ascorbic acid therapy decreases organ failure by providing a protective effect on several microvascular functions including improving capillary blood flow, decreasing microvascular permeability, and improving arteriolar responsiveness to vasoconstrictors. Defining the utility of novel agents to augment researchers care for severe sepsis is an important task as investigators continue the institutional focus on sepsis care.

Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.

Description:
ASCOR (ascorbic acid injection) for intravenous use is a colorless to pale yellow, preservative-free, hypertonic, sterile, non-pyrogenic solution of ascorbic acid. ASCOR must be diluted with an appropriate infusion solution.

Each ASCOR, 50 mL, Pharmacy Bulk Package vial contains 25,000 mg ascorbic acid, equivalent to 28,125 mg sodium ascorbate.

Each mL of ASCOR contains 500 mg of ascorbic acid (equivalent to 562.5 mg of sodium ascorbate which amounts to 65 mg sodium/mL of ASCOR), 0.25 mg of edetate disodium, and water for injection. Sodium hydroxide and sodium bicarbonate are added for pH adjustment (pH range 5.6 to 6.6). It contains no bacteriostatic or antimicrobial agent.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

The exact mechanism of action of ascorbic acid for the treatment of symptoms and signs of scurvy (a disorder caused by severe deficiency in vitamin C) is unknown; however, administration of ascorbic acid in patients with scurvy is thought to restore the body pool of ascorbic acid.

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:
ASCOR ® is indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients, age 5 months and older, for whom oral administration is not possible, insufficient or contraindicated.

Limitations of Use:
ASCOR is not indicated for the treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.

Several unlabled uses have been studied. Please review the recent literature for updated guidelines.

CONTRAINDICATIONS Return to article top

Contraindications:

None.

WARNINGS AND PRECAUTIONS:
5.1 Oxalate Nephropathy and Nephrolithiasis
Acute and chronic oxalate nephropathy have been reported with prolonged administration of high doses of ascorbic acid. Acidification of the urine by ascorbic acid may cause precipitation of cysteine, urate or oxalate stones. Patients with renal disease including renal impairment, history of oxalate kidney stones, and geriatric patients may be at increased risk for oxalate nephropathy while receiving treatment with ascorbic acid. Pediatric patients less than 2 years of age may be at increased risk for oxalate nephropathy during treatment with ascorbic acid because their kidneys are immature [see Use in Specific Populations ( 8.4, 8.5, 8.6)]. Monitor renal function in patients at increased risk receiving ASCOR. Discontinue ASCOR in patients who develop oxalate nephropathy and treat any suspected oxalate nephropathy.

ASCOR is not indicated for prolonged administration (the maximum recommended duration is one week)

5.2 Hemolysis in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency
Hemolysis has been reported with administration of ascorbic acid in patients with glucose-6-phosphate dehydrogenase deficiency. Patients with glucose-6-phosphate dehydrogenase may be at increased risk for severe hemolysis during treatment with ascorbic acid. Monitor hemoglobin and blood count and use a reduced dose of ASCOR in patients with glucose-6-phosphate dehydrogenase deficiency. Discontinue treatment with ASCOR if hemolysis is suspected and treat as needed.

5.3 Laboratory Test Interference
Ascorbic acid may interfere with laboratory tests based on oxidation-reduction reactions, including blood and urine glucose testing, nitrite and bilirubin levels, and leucocyte count testing. If possible, laboratory tests based on oxidation-reduction reactions should be delayed until 24 hours after infusion of ASCOR.

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide. Drug information

DOSAGE AND ADMINISTRATION Return to article top

2.1 Important Preparation and Administration Instructions
  • ASCOR vials contain 25, 000 mg of ascorbic acid and the largest recommended single dose is 200 mg. Do not give the entire contents of the vial to a single patient.
  • Do not administer ASCOR as an undiluted intravenous sensitive.
  • Minimize exposure to light because ASCOR is light sensitive.
  • ASCOR is supplied as a Pharmacy Bulk Package (PBP) which is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion:

a. Use only in a suitable ISO Class 5 work area such as a laminar flow hood (or an equivalent clean air compounding area)

b. Penetrate each PBP vial closure only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. Given that pressure may develop within the vial during storage, excercise caution when withdrawing contents from the vial.

c. Once the closure system has been penetrated, complete all dispensing from the PBP vial within 4 hours. Each dose must be used immediately. Discard unused portion.

d. Prior to administration, ASCOR must be diluted in a suitable infusion solution and the final solution for infusion must be isotonic (undiluted the osmolarity of ASCOR is approximately 5,900 mOsmol/L). Prior to preparing the admixture for infusion, calculate the osmolarity of the intended admixture for infusion. Add one daily dose of ASCOR directly to an appropriate volume of a suitable infusion solution (e.g., 5% Dextrose Injection, Sterile Water for Injection) and add appropriate solutes, as necessary, to make final solution isotonic. Sterile Water for Injection is highly hypotonic; adjust solute content, as necessary, to make thet final infusion solution isotonic prior to injection. Do not mix ASCOR with solutions containing elemental compounds that can be reduced (e.g., copper). The concentration of ascorbic acid in the final, admixture solution for infusion is to be the range of 1 to 25 mg of ascorbic acid per mL. For example, for the largest recommended dose:

Add 200 mg of ascorbic acid (equivalent to 0.4 mL of ASCOR) to 7.5 mL of Sterile Water for Injection to produce an infusion solution having an approximate osmolarity of 290 mOsmol/L. In this specific example, addition of solute is NOT necessary because the solution is isotonic.

e. Prepare the recommended dose based on the patient population.

f. Visually inspect for particulate matter and discoloration prior to administration (the diluted ASCOR solution should appear colorless to pale yellow).

g. Immediately administer the admixture for infusion as a slow intravenous infusion.

2.2 Recommended Dosage

Table 1 provides recommended doses of ASCOR based on patient population and infusion rates of diluted ASCOR solution.

Table 1: Recommended Dose of ASCOR and Infusion Rate of Diluted ASCOR Solution
Patient Population ASCOR
Once Daily Dose
(mg)		 Infusion Rate of
Diluted ASCOR
Solution (mg/minute)
Pediatric Patients age 5 months to less than 12 months 50 1.3
Pediatric Patients age 1 year to less than 11 years 100 3.3
Adults and Pediatric Patients 11 years and older 200 33

The recommended maximum duration of daily treatment with ASCOR is seven days. If no improvement in scorbutic symptoms is observed after one week of treatment, retreat until resolution of scorbutic symptoms is observed.

Repeat dosing is not recommended in pediatric patients less than 11 years of age.

2.3 Dosage Reductions in Specific Populations

Women who are pregnant or lactating and patients with glucose-6-dehydrogenase deficiency should not exceed the U.S. Recommended Dietary Allowance (RDA) or daily Adequate Intake (AI) level for ascorbic acid for their age group and condition and Use in Specific Populations.

DOSAGE FORMS AND STRENGTHS:

Injection: 25,000 mg/50 mL (500 mg/mL) supplied as a Pharmacy Bulk Package (clear, colorless to pale yellow solution)

Storage and Stability Return to article top

Store in a refrigerator at 2° to 8°C (36° to 46°F).

Protect from light. This product contains no preservative.

See Dosage and Administration (2.1), for detailed instructions on preparation, dilution, and administration of ASCOR.

Reference Return to article top

Trissel's™ 2 Clinical Pharmaceutics Database (Parenteral Compatibility

  • Accessed: December 02, 2020
  • Findings: Ascorbic acid: concentrations: 1mg/mL and 10 mg/mL.
    Solution: NS. Compatible. 10 mg/mL: 3 to 6% loss at 24 hours room temperature.
  • Ascorbic acid: concentrations: 1mg/mL and 10 mg/mL.
    Solution: D5W.. Compatible. 10 mg/mL: No ascorbic acid loss occurred within the study period.

Reference Return to article top

Walker SE, Iazzetta J, Law S, et al. Administration of Intravenous Ascorbic Acid-Practical Considerations for Clinicians. Nutrients. 2019;11(9):1994. Published 2019 Aug 23. doi:10.3390/nu11091994

  • Emerging data suggest that intravenous ascorbic acid (AA) may be beneficial in patients with sepsis. Clinicians require data on stability of diluted AA for safe administration. We evaluated the stability of AA diluted in normal saline (NS) or 5% dextrose in water (D5W) solutions over 14 days at 25 °C and at 4 °C, protected from light, using concentrations of 37 mg/mL and 77 mg/mL (Sandoz) and 40 mg/mL and 92 mg/mL (Mylan). We also assessed stability of a 40 mg/mL solution (Mylan) at 25 °C exposed to light for 75 h.
  • Evaluation of the Need to Protect from Light
    During the 75 h evaluation period, AA exposed to fluorescent room light at 25 °C nominally degraded faster than samples protected from light (Table 3). AA stored in the administration sets degraded to 95.15% remaining when exposed to light, compared to 96.79% remaining when protected from light (p = 0.948 for difference in degradation rate to 75 h). Similar rates of degradation were observed in PVC minibags (p = 0.681 for difference in degradation rate).
  • This study demonstrates that AA solutions at concentrations between 37 and 92 mg/mL, diluted in either NS or D5W and stored in PVC minibags, are physically, chemically and visually stable for at least 14 days refrigerated at 4 °C with protection from light. Clinicians in acute care settings may consider using AA solutions stored under these conditions. By contrast, when stored at room temperature (25 °C), AA solutions remained stable for 10 days, but discolouration was apparent after 2 days, possibly indicating degradation products of uncertain safety.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ascorbic-acid-injection
      Source IDH51-8BF7DF281E34CB2C1359E51C
      Generic name
      Ascorbic acid injection
      Source IDH51-2FEA289666C1F509E2AAA338
      Class
      Other intravenous medications
      Source IDH51-D57BFE1EB63D4BCC454B1DD8
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-60E794E7B88BD32A263BFBA4
      Primary uses
      1. A specialized IV indication that requires confirmation in the current exact-product label and applicable specialty guidance.
        Source IDH51-BD682A9772A5C285F66D1497
      Mechanism
      Functions as a reducing agent and cofactor in collagen, catecholamine, carnitine, and antioxidant pathways.
      Source IDH51-1B83713644F85C9A409F45C3
      Mechanism level
      drug_specific
      Source IDH51-2FF32270AF648B129459A353
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-F0B48626F5690E0B391EB416
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-EC898B61E14EE67032591183
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-B51BA54942E1072D276B2152
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-A601DF317A64655EC47389B9
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-A5B38FA12B8E73E9E4F189DA
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-4B5D5643FDA5D8BB7F9D0473
      Legacy title
      Ascorbic acid injection
      Source IDH51-5503D1A8B098B467647D0878
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-CB0A09B531FD4232D2F66A39
      Search text
      Ascorbic acid injection Other intravenous medications Legacy GlobalRPh directory entry A specialized IV indication that requires confirmation in the current exact-product label and applicable specialty guidance. Functions as a reducing agent and cofactor in collagen, catecholamine, carnitine, and antioxidant pathways. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-192D0E83AFF9A09173042A37
      Official access mode
      none
      Source IDH51-2061D372E7504157EBD61BF4
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-BAD2E683EFD12A37D931B5E2

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-4D1F708F6E6C4C696B1D5457
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-7E07A04C0B0EB58124284135
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-6AD06878E077466C5DD52879

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-858EDD3459DC4A73C005089B

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-4FC07ABA403A0C89A92534DB
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      ascorbic-acid-injection
      Source IDH51-DB8A53EBBC098B5DDC1F17BB
      Legacy title
      Ascorbic acid injection
      Source IDH51-7840DE847A7396C24F955907
      Generic name
      Ascorbic acid injection
      Source IDH51-5CEE62FD2F92AF510975848C
      Class
      Other intravenous medications
      Source IDH51-BB48A9D28BB6168A641AD0CC
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-08858EE2D9184D7CE1C2E5D3
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-EFDDE0E21915054C448D9E39
      Populations
      1. Population not yet normalized
        Source IDH51-39EE1B8E8D7C4BDFEC1CEE24
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-2F9A2CA5D37D92E0DC2BE8D2
      High alert
      false
      Source IDH51-900FC004F831056FE98A8493
      Hazardous
      false
      Source IDH51-A2B6EE4E5F879F501B8493D6
      Status
      Legacy migration
      Source IDH51-6AA5C0BB6C563A920AA9FC5B
      Version added
      Legacy
      Source IDH51-0E5C5DC425E112C6458EC4F7
      Sources
      LabelUrlKind
      Source IDH51-D0CE2D49D781E1CF8EBB0707
      GlobalRPh legacy IV dilution monograph
      Source IDH51-672766267CC7FEB5E195DBFD
      		legacy:auto
      Source IDH51-D5A083768BB0BE3B839A2670
      		Legacy
      Source IDH51-3E3771D05069F4AD513ACC76
      Clinical release verification
      Audit version
      3.4
      Source IDH51-00ACC48D18E673805AF09E5A
      Audited on
      2026-08-30
      Source IDH51-079ED449B0EB445660E6A9B5
      Level
      red
      Source IDH51-516B51DF631DB7C82E4E9BEA
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-CB58EE7D3933048FD831F6C7
      Exact current label candidate
      false
      Source IDH51-0BD1A5911E50699304ECA2B7
      Reference url count
      0
      Source IDH51-B89387DA96EF25CFF85CBC6C
      Broken reference count
      0
      Source IDH51-9D769E6369F79ABC2DC78B5A
      Point of use confirmation required
      true
      Source IDH51-C4F6ACC3B43E2822487F84BD
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-650C1336E42ABE04312BCD65

      Dosing source fields

      Id
      ascorbic-acid-injection
      Source IDH51-22DC8B3C0E38963E3EBDB28D
      Generic name
      Ascorbic acid injection
      Source IDH51-435B9EF4293AD20F11EA4262
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-296E3F293032EFD095C21C38
      Package insert
      Query name
      Ascorbic acid injection
      Source IDH51-C8C86BE3CB6B8816AA386FDF
      Product and route must match
      true
      Source IDH51-4288342ACDDDBBB501DE3CD4
      Live current label enabled
      false
      Source IDH51-630A593E2C4EEC28658A5589
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-B1880F0720BDC97D397E50D0
      Direct official label access enabled
      true
      Source IDH51-27E3D091C12900150D899488
      Outbound server request required
      false
      Source IDH51-2837148B78DB3B16B2351D96
      Local summary status
      not_bundled
      Source IDH51-05ADB12093D680D46289D8AF
      Clinical review
      Locally normalized
      false
      Source IDH51-CCA50E8D849329C5CB25BF24
      Reviewed
      2026-08-29
      Source IDH51-3BD595DDCB4B6AAE4210C28F
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-932A02FD351713E6638B9D08
      Clinical release verification
      Audit version
      3.4
      Source IDH51-8C4C969444441110943DE4A8
      Audited on
      2026-08-30
      Source IDH51-56EC4D5FA5976EBF204B5195
      Level
      red
      Source IDH51-F1FBA241D5AA9D2A4542C985
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-5BB59F0BC0BD05F509EC57A8
      Exact current label candidate
      false
      Source IDH51-90FEB15A4F0B91F49370B683
      Reference url count
      0
      Source IDH51-918302896170053E41193597
      Broken reference count
      0
      Source IDH51-36661E82F602F8320AC4D210
      Point of use confirmation required
      true
      Source IDH51-714504963E81F907EC083843
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-926D5B27D4739277C6415865
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ascorbic-acid-injection
      Source IDH51-169CFE21E5009F1FCDB0E386
      Name
      Ascorbic acid injection
      Source IDH51-469779E08BFAE7663B4B3F62
      Therapeutic class
      Other intravenous medications
      Source IDH51-AA94219CDBB8D3D36B2495B9
      Review version
      3.1
      Source IDH51-1DCDB16579ECB77EC0C20576
      Review date
      2026-08-30
      Source IDH51-D4B39B81328013EE1E13D4D2
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-D2DFEB1898ABA12529656416
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-6475E32B0DBDAD5A1E62EF4B
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-1F3B925323B23EF5135C96EA
      Ten point assessment
      Exact formulation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)id: ascorbic-acid-injection | generic_name: Ascorbic acid injection | coverage_status: package_insert_live_plus_legacy_reference | package_insert: query_name: Ascorbic acid injection | product_and_route_must_match: true | live_current_label_enabled: true | source_priority: 1 | renal: classification: current_label_review_required | summary: Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. | method_note: Use the renal function estimate and body-size convention specified by the selected label or institutional protocol.
      Source IDH51-2DDD11C386D04B35D103533F
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-45742BC426DA08E5BBAC9AA4
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-CE48B7450240A4E0DACA35A6
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-126AD784B81D08C7533D671C
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-F34ADC52ED28AFB2165072D5
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-D36ED372E96477E038D7604B
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-1FD61261FC36E4CB4DE5C061
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-58ADE6E82A18F0EA3464E3AD
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-8F88A6D1018033E8EF0EA84C
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-6A7DA8707B7674C3D162EA9E
      Field provenance
      Exact formulation
      Primary
      existing_record_text
      Source IDH51-EC851D4993BFED419650CBD6
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-8802C31071C90B88AB8A9EFE
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-24AD275B9822AEC46DB56EE8
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-4BC468CFA2FCED30881D9F98
      Adult dosing range
      Primary
      not_found
      Source IDH51-517D29308E72624756DED4BB
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-1ED75C2837F1B26CB2804439
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-4ACD2EA546DE3EDD8860DA8B
      Infusion time
      Primary
      not_found
      Source IDH51-89E64C00ED72DC181B7110F0
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-3DFFFE990C56573E29E74546
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-722227619EE579C444E3E405
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-5DC2CD24C5DF87C01566A9D4
      Guide generation allowed
      false
      Source IDH51-C34D968C83E8CE2A34948657
      Pediatric
      Applicability
      not_established
      Source IDH51-A043EBFF1D09FE7FAD27E6EE
      Guide generation allowed
      false
      Source IDH51-D0F6558F5D90AD54956E3FEF
      Neonatal
      Applicability
      not_established
      Source IDH51-3D7F5489E100C7419CA8B5F3
      Guide generation allowed
      false
      Source IDH51-515BE985C20F1C383F847431
      Route presence
      Structured dilution
      false
      Source IDH51-35C04D31FB9BC162F59B5A66
      Iv push
      false
      Source IDH51-2BF8B6C01CFF3B356EB0888E
      Continuous infusion
      false
      Source IDH51-84EDCB143B198126C81E13EF
      Pediatric source
      false
      Source IDH51-E6AE3087A405D3932CAC93CD
      Neonatal source
      false
      Source IDH51-073C3D7DD605BB157F99CAD9
      Legacy reference
      Status
      not_available
      Source IDH51-F4E696F00B80EF4CA45F52AA
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-EE6F1AA756658DAD34D1C6FA
      Source files
      1. catalog.json
        Source IDH51-0B5374149320DE8D8449495A
      2. dosing.json
        Source IDH51-5F4709F1F559F708F5FC1ABA
      3. legacy-map.json
        Source IDH51-050C2A7D4B80ED869363D91D
      4. review-queue.json
        Source IDH51-536413892EC9E37D3BADB4C1
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-12913729A435945CC466D37A
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-DB8A53EBBC098B5DDC1F17BBcatalog.json
      /records/26/id      		Historical; current review incomplete
      H51-7840DE847A7396C24F955907catalog.json
      /records/26/legacy_title      		Historical; current review incomplete
      H51-5CEE62FD2F92AF510975848Ccatalog.json
      /records/26/generic_name      		Historical; current review incomplete
      H51-BB48A9D28BB6168A641AD0CCcatalog.json
      /records/26/class      		Historical; current review incomplete
      H51-08858EE2D9184D7CE1C2E5D3catalog.json
      /records/26/subclass      		Historical; current review incomplete
      H51-EFDDE0E21915054C448D9E39catalog.json
      /records/26/summary      		Historical; current review incomplete
      H51-858EDD3459DC4A73C005089Bcatalog.json
      /records/26/warnings/0      		Historical; current review incomplete
      H51-4FC07ABA403A0C89A92534DBcatalog.json
      /records/26/stability_notes/0      		Historical; current review incomplete
      H51-39EE1B8E8D7C4BDFEC1CEE24catalog.json
      /records/26/populations/0      		Historical; current review incomplete
      H51-2F9A2CA5D37D92E0DC2BE8D2catalog.json
      /records/26/evidence_tier      		Historical; current review incomplete
      H51-900FC004F831056FE98A8493catalog.json
      /records/26/high_alert      		Historical; current review incomplete
      H51-A2B6EE4E5F879F501B8493D6catalog.json
      /records/26/hazardous      		Historical; current review incomplete
      H51-6AA5C0BB6C563A920AA9FC5Bcatalog.json
      /records/26/status      		Historical; current review incomplete
      H51-FFA99595DFDAE1FEFC99223Fcatalog.json
      /records/26/reviewed      		Historical; current review incomplete
      H51-0E5C5DC425E112C6458EC4F7catalog.json
      /records/26/version_added      		Historical; current review incomplete
      H51-D0CE2D49D781E1CF8EBB0707catalog.json
      /records/26/sources/0      		Historical; current review incomplete
      H51-672766267CC7FEB5E195DBFDcatalog.json
      /records/26/sources/0/label      		Historical; current review incomplete
      H51-D5A083768BB0BE3B839A2670catalog.json
      /records/26/sources/0/url      		Historical; current review incomplete
      H51-3E3771D05069F4AD513ACC76catalog.json
      /records/26/sources/0/kind      		Historical; current review incomplete
      H51-00ACC48D18E673805AF09E5Acatalog.json
      /records/26/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-079ED449B0EB445660E6A9B5catalog.json
      /records/26/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-516B51DF631DB7C82E4E9BEAcatalog.json
      /records/26/clinical_release_verification/level      		Historical; current review incomplete
      H51-CB58EE7D3933048FD831F6C7catalog.json
      /records/26/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-0BD1A5911E50699304ECA2B7catalog.json
      /records/26/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-B237F657A58C523465C4F096catalog.json
      /records/26/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-DFE6308EEF2A7F1C263095B3catalog.json
      /records/26/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-8481FAED369D2DFDA3990C9Ccatalog.json
      /records/26/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-B89387DA96EF25CFF85CBC6Ccatalog.json
      /records/26/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-9D769E6369F79ABC2DC78B5Acatalog.json
      /records/26/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-C4F6ACC3B43E2822487F84BDcatalog.json
      /records/26/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-650C1336E42ABE04312BCD65catalog.json
      /records/26/clinical_release_verification/note      		Historical; current review incomplete
      H51-CB26211DEAA76B14EFCBBEBEcatalog.json
      /records/26/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-22DC8B3C0E38963E3EBDB28Ddosing.json
      /records/26/id      		Historical; current review incomplete
      H51-435B9EF4293AD20F11EA4262dosing.json
      /records/26/generic_name      		Historical; current review incomplete
      H51-296E3F293032EFD095C21C38dosing.json
      /records/26/coverage_status      		Historical; current review incomplete
      H51-C8C86BE3CB6B8816AA386FDFdosing.json
      /records/26/package_insert/query_name      		Historical; current review incomplete
      H51-0B8911017DF8B317D1B02922dosing.json
      /records/26/package_insert/preferred_setid      		Historical; current review incomplete
      H51-4288342ACDDDBBB501DE3CD4dosing.json
      /records/26/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-630A593E2C4EEC28658A5589dosing.json
      /records/26/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-B1880F0720BDC97D397E50D0dosing.json
      /records/26/package_insert/source_priority      		Historical; current review incomplete
      H51-27E3D091C12900150D899488dosing.json
      /records/26/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-2837148B78DB3B16B2351D96dosing.json
      /records/26/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-05ADB12093D680D46289D8AFdosing.json
      /records/26/package_insert/local_summary_status      		Historical; current review incomplete
      H51-4D1F708F6E6C4C696B1D5457dosing.json
      /records/26/renal/classification      		Historical; current review incomplete
      H51-7E07A04C0B0EB58124284135dosing.json
      /records/26/renal/summary      		Historical; current review incomplete
      H51-6AD06878E077466C5DD52879dosing.json
      /records/26/renal/method_note      		Historical; current review incomplete
      H51-CCA50E8D849329C5CB25BF24dosing.json
      /records/26/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-3BD595DDCB4B6AAE4210C28Fdosing.json
      /records/26/clinical_review/reviewed      		Historical; current review incomplete
      H51-932A02FD351713E6638B9D08dosing.json
      /records/26/clinical_review/status      		Historical; current review incomplete
      H51-8C4C969444441110943DE4A8dosing.json
      /records/26/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-56EC4D5FA5976EBF204B5195dosing.json
      /records/26/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-F1FBA241D5AA9D2A4542C985dosing.json
      /records/26/clinical_release_verification/level      		Historical; current review incomplete
      H51-5BB59F0BC0BD05F509EC57A8dosing.json
      /records/26/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-90FEB15A4F0B91F49370B683dosing.json
      /records/26/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-7B6CD034A9858E9E943CD191dosing.json
      /records/26/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-01DA07F1FE837C79F2F59748dosing.json
      /records/26/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-8A0DA40B3D226A8E2EE60DC0dosing.json
      /records/26/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-918302896170053E41193597dosing.json
      /records/26/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-36661E82F602F8320AC4D210dosing.json
      /records/26/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-714504963E81F907EC083843dosing.json
      /records/26/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-926D5B27D4739277C6415865dosing.json
      /records/26/clinical_release_verification/note      		Historical; current review incomplete
      H51-934E310E698C77560AA909DAdosing.json
      /records/26/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-8BF7DF281E34CB2C1359E51Cfirst-look-v5.1.json
      /records/26/id      		Historical; current review incomplete
      H51-2FEA289666C1F509E2AAA338first-look-v5.1.json
      /records/26/generic_name      		Historical; current review incomplete
      H51-D57BFE1EB63D4BCC454B1DD8first-look-v5.1.json
      /records/26/class      		Historical; current review incomplete
      H51-60E794E7B88BD32A263BFBA4first-look-v5.1.json
      /records/26/subclass      		Historical; current review incomplete
      H51-BD682A9772A5C285F66D1497first-look-v5.1.json
      /records/26/primary_uses/0      		Historical; current review incomplete
      H51-1B83713644F85C9A409F45C3first-look-v5.1.json
      /records/26/mechanism      		Historical; current review incomplete
      H51-2FF32270AF648B129459A353first-look-v5.1.json
      /records/26/mechanism_level      		Historical; current review incomplete
      H51-F0B48626F5690E0B391EB416first-look-v5.1.json
      /records/26/basic_dosing_orientation      		Historical; current review incomplete
      H51-EC898B61E14EE67032591183first-look-v5.1.json
      /records/26/administration_orientation      		Historical; current review incomplete
      H51-B51BA54942E1072D276B2152first-look-v5.1.json
      /records/26/renal_and_population_orientation      		Historical; current review incomplete
      H51-A601DF317A64655EC47389B9first-look-v5.1.json
      /records/26/key_safety_orientation/0      		Historical; current review incomplete
      H51-A5B38FA12B8E73E9E4F189DAfirst-look-v5.1.json
      /records/26/coverage_path      		Historical; current review incomplete
      H51-4B5D5643FDA5D8BB7F9D0473first-look-v5.1.json
      /records/26/coverage_path_label      		Historical; current review incomplete
      H51-FF59D04AF13CA81486EA19A0first-look-v5.1.json
      /records/26/official_label_url      		Historical; current review incomplete
      H51-5503D1A8B098B467647D0878first-look-v5.1.json
      /records/26/legacy_title      		Historical; current review incomplete
      H51-CB0A09B531FD4232D2F66A39first-look-v5.1.json
      /records/26/review_note      		Historical; current review incomplete
      H51-192D0E83AFF9A09173042A37first-look-v5.1.json
      /records/26/search_text      		Historical; current review incomplete
      H51-0DF1E5521EF597901FB12184first-look-v5.1.json
      /records/26/official_search_url      		Historical; current review incomplete
      H51-2061D372E7504157EBD61BF4first-look-v5.1.json
      /records/26/official_access_mode      		Historical; current review incomplete
      H51-F4E750F5C0C1A3480D5039FFfirst-look-v5.1.json
      /records/26/official_access_url      		Historical; current review incomplete
      H51-497792CE7DB6D1FB7480B859first-look-v5.1.json
      /records/26/official_search_query      		Historical; current review incomplete
      H51-BAD2E683EFD12A37D931B5E2first-look-v5.1.json
      /records/26/official_access_reason      		Historical; current review incomplete
      H51-169CFE21E5009F1FCDB0E386preparation-assessments-v3.8.json
      /26/id      		Historical; current review incomplete
      H51-469779E08BFAE7663B4B3F62preparation-assessments-v3.8.json
      /26/name      		Historical; current review incomplete
      H51-D46AAE3BC21ED102791CF4C9preparation-assessments-v3.8.json
      /26/brands      		Historical; current review incomplete
      H51-AA94219CDBB8D3D36B2495B9preparation-assessments-v3.8.json
      /26/therapeutic_class      		Historical; current review incomplete
      H51-1DCDB16579ECB77EC0C20576preparation-assessments-v3.8.json
      /26/review_version      		Historical; current review incomplete
      H51-D4B39B81328013EE1E13D4D2preparation-assessments-v3.8.json
      /26/review_date      		Historical; current review incomplete
      H51-D2DFEB1898ABA12529656416preparation-assessments-v3.8.json
      /26/release_status      		Historical; current review incomplete
      H51-6475E32B0DBDAD5A1E62EF4Bpreparation-assessments-v3.8.json
      /26/market_status/status      		Historical; current review incomplete
      H51-1F3B925323B23EF5135C96EApreparation-assessments-v3.8.json
      /26/market_status/basis      		Historical; current review incomplete
      H51-2DDD11C386D04B35D103533Fpreparation-assessments-v3.8.json
      /26/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-45742BC426DA08E5BBAC9AA4preparation-assessments-v3.8.json
      /26/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-CE48B7450240A4E0DACA35A6preparation-assessments-v3.8.json
      /26/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-126AD784B81D08C7533D671Cpreparation-assessments-v3.8.json
      /26/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-F34ADC52ED28AFB2165072D5preparation-assessments-v3.8.json
      /26/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-D36ED372E96477E038D7604Bpreparation-assessments-v3.8.json
      /26/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-1FD61261FC36E4CB4DE5C061preparation-assessments-v3.8.json
      /26/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-58ADE6E82A18F0EA3464E3ADpreparation-assessments-v3.8.json
      /26/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-8F88A6D1018033E8EF0EA84Cpreparation-assessments-v3.8.json
      /26/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-1F78108DE8B43E50C35C7813preparation-assessments-v3.8.json
      /26/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-0E6E465DE743216089586C63preparation-assessments-v3.8.json
      /26/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-9D2D36418C0DC6F3239EA810preparation-assessments-v3.8.json
      /26/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-A2417D9EB2A9D33C440C1AB1preparation-assessments-v3.8.json
      /26/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-6A7DA8707B7674C3D162EA9Epreparation-assessments-v3.8.json
      /26/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-AB7993667F2D2E2BADC8F929preparation-assessments-v3.8.json
      /26/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-EC851D4993BFED419650CBD6preparation-assessments-v3.8.json
      /26/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-8802C31071C90B88AB8A9EFEpreparation-assessments-v3.8.json
      /26/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-24AD275B9822AEC46DB56EE8preparation-assessments-v3.8.json
      /26/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-4BC468CFA2FCED30881D9F98preparation-assessments-v3.8.json
      /26/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-517D29308E72624756DED4BBpreparation-assessments-v3.8.json
      /26/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-1ED75C2837F1B26CB2804439preparation-assessments-v3.8.json
      /26/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-4ACD2EA546DE3EDD8860DA8Bpreparation-assessments-v3.8.json
      /26/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-89E64C00ED72DC181B7110F0preparation-assessments-v3.8.json
      /26/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-3DFFFE990C56573E29E74546preparation-assessments-v3.8.json
      /26/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-722227619EE579C444E3E405preparation-assessments-v3.8.json
      /26/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-5DC2CD24C5DF87C01566A9D4preparation-assessments-v3.8.json
      /26/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-C34D968C83E8CE2A34948657preparation-assessments-v3.8.json
      /26/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-A043EBFF1D09FE7FAD27E6EEpreparation-assessments-v3.8.json
      /26/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-D0F6558F5D90AD54956E3FEFpreparation-assessments-v3.8.json
      /26/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-3D7F5489E100C7419CA8B5F3preparation-assessments-v3.8.json
      /26/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-515BE985C20F1C383F847431preparation-assessments-v3.8.json
      /26/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-35C04D31FB9BC162F59B5A66preparation-assessments-v3.8.json
      /26/route_presence/structured_dilution      		Historical; current review incomplete
      H51-2BF8B6C01CFF3B356EB0888Epreparation-assessments-v3.8.json
      /26/route_presence/iv_push      		Historical; current review incomplete
      H51-84EDCB143B198126C81E13EFpreparation-assessments-v3.8.json
      /26/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-E6AE3087A405D3932CAC93CDpreparation-assessments-v3.8.json
      /26/route_presence/pediatric_source      		Historical; current review incomplete
      H51-073C3D7DD605BB157F99CAD9preparation-assessments-v3.8.json
      /26/route_presence/neonatal_source      		Historical; current review incomplete
      H51-F4E696F00B80EF4CA45F52AApreparation-assessments-v3.8.json
      /26/legacy_reference/status      		Historical; current review incomplete
      H51-EE6F1AA756658DAD34D1C6FApreparation-assessments-v3.8.json
      /26/label_resolution/status      		Historical; current review incomplete
      H51-0B5374149320DE8D8449495Apreparation-assessments-v3.8.json
      /26/source_files/0      		Historical; current review incomplete
      H51-5F4709F1F559F708F5FC1ABApreparation-assessments-v3.8.json
      /26/source_files/1      		Historical; current review incomplete
      H51-050C2A7D4B80ED869363D91Dpreparation-assessments-v3.8.json
      /26/source_files/2      		Historical; current review incomplete
      H51-536413892EC9E37D3BADB4C1preparation-assessments-v3.8.json
      /26/source_files/3      		Historical; current review incomplete
      H51-12913729A435945CC466D37Apreparation-assessments-v3.8.json
      /26/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top